NCT
Phase
Entity
0257
2687
I
Durvalumab
and
Ramucirumab
(Gastric Cancer, HCC and
NSCLC)
0268
1549
II
Pembrolizumab
and
Bevacizumab
in patients with
untreated brain metastases
(melanoma, NSCLC)
Several phase III trials exploring combinations
of
nivolumab, atezolizumab, durvalumab
and pembrolizumab
with
platinum based
chemotherapy and bevacizumab
Phase I Study:
Pembrolizumab + Ramucirumab
Herbst R, ESMO 2016
Predictive Markers
of Paramount Importance!
Combined inhibition of tumor
Angiogenesis and Immune checkpoints
